Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy

Several tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptors and molecules inhibiting the mammalian target of rapamycin are being used for management of metastatic renal cell carcinoma (mRCC); however, there is still a potential for improvement. Immune checkpoint inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Venur, Vyshak Alva, Joshi, Monika, Nepple, Kenneth G, Zakharia, Yousef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395273/
https://www.ncbi.nlm.nih.gov/pubmed/28442891
http://dx.doi.org/10.2147/DDDT.S110209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395273/
https://www.ncbi.nlm.nih.gov/pubmed/28442891
http://dx.doi.org/10.2147/DDDT.S110209

Ejemplares similares